Global Anti-migraine Drugs Market US$ 9.5 Billion by 2025, page-5

First 5 Last

Share
Profile

Follow
Wasabibarako

9,660 Posts.

145

26/03/19

07:52

Post #: 37881067
Share

Originally posted by Bluebush: ↑

Thanks for he kind words old mate, but I really don't know nothin'. I'm still in cause I reckon that there is a chance that we just might jag something (big). Carter's not a sniper, so for him to focus on one product only, would be a mistake. But shotguns are different and even a mug can hit something. Big dog's recent comments about Carter's enthusiasm for Anagrelide could very well be significant. Plenty of irons in the fire at the moment which means there's some redundancy. I reckon stiffy-mist might fall into that category.

A realistic comparison is ACR which peaked at a MC of over 400 million when Eli Lilly started selling their testosterone product. Problem was they only had one product of substance and I think it's fair to say that the FDA investigation into cardio-respiratory issues associated with testosterone supplements as well as the failure to prevent generics in the market killed that run.

Anyway, all good.

Expand

Originally posted by Bluebush: ↑

Thanks for he kind words old mate, but I really don't know nothin'. I'm still in cause I reckon that there is a chance that we just might jag something (big). Carter's not a sniper, so for him to focus on one product only, would be a mistake. But shotguns are different and even a mug can hit something. Big dog's recent comments about Carter's enthusiasm for Anagrelide could very well be significant. Plenty of irons in the fire at the moment which means there's some redundancy. I reckon stiffy-mist might fall into that category.

A realistic comparison is ACR which peaked at a MC of over 400 million when Eli Lilly started selling their testosterone product. Problem was they only had one product of substance and I think it's fair to say that the FDA investigation into cardio-respiratory issues associated with testosterone supplements as well as the failure to prevent generics in the market killed that run.

Anyway, all good.

Expand

Bluebush: "Anyway, all good."

So you guys must really be ENJOYING the new share-price of 0.004.... ?!?

wasa

SUD Price at posting: 0.4¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

There are more pages in this discussion • 4 more messages in this thread...

First 5 Last

Add SUD (ASX) to my watchlist

Global Anti-migraine Drugs Market US$ 9.5 Billion by 2025, page-5

Top Stories

Scientific conference spotlights PYC's work on blindness disease treatment

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Sales growth pushes Lovisa's fortunes (and shares) upwards

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse